Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Lars Fruergaard Jørgensen
CEOLars Fruergaard Jørgensen
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1931
Founded1931
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
273.92B
Market cap273.92B
Price-Earnings ratio
18.22
Price-Earnings ratio18.22
Dividend yield
1.97%
Dividend yield1.97%
Average volume
12.14M
Average volume12.14M
High today
$62.43
High today$62.43
Low today
$60.89
Low today$60.89
Open price
$61.80
Open price$61.80
Volume
9.13M
Volume9.13M
52 Week high
$148.15
52 Week high$148.15
52 Week low
$57.00
52 Week low$57.00

NVO News

Sherwood News 2d
Novo Nordisk slumps following trial results for Eli Lilly's weight-loss pill

Novo Nordisk , the Danish maker of Ozempic and Wegovy, fell almost 10% early on Tuesday — its first trading session since rival Eli Lilly unveiled strong trial...

Novo Nordisk slumps following trial results for Eli Lilly's weight-loss pill
TipRanks 5d
Novo Nordisk Faces Stock Dip Amidst Market Challenges

Novo Nordisk ( (NVO) ) has fallen by -12.08%. Read on to learn why. Novo Nordisk has experienced a notable decline in its stock price, dropping by 12.08% over...

Benzinga 6d
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React

Eli Lilly & Co. LLY shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its l...

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React

Analyst ratings

62%

of 34 ratings
Buy
61.8%
Hold
29.4%
Sell
8.8%

More NVO News

TipRanks 6d
Novo Nordisk downgraded to Neutral from Buy at Guggenheim

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Benzinga 6d
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock

BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk NVO from Outperform to Market Perform, lowering the price forecast from $105 to $64. P...

Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Sherwood News 7d
Eli Lilly rises after weight-loss pill succeeds in trials

Eli Lilly rises after weight-loss pill succeeds in trials Eli Lilly’s once-daily weight-loss pill, orforglipron, succeeded in early trails with results similar...

Eli Lilly rises after weight-loss pill succeeds in trials
TipRanks 7d
Leerink bullish on Eli Lilly after ‘picture-perfect’ Phase 3 oral GLP-1 results

Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (N...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.